Indications
Zolgensma is indicated for the treatment of: patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.
Composition
- Active substance
- onasemnogene abeparvovec
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zolgensma
- Active substance
- onasemnogene abeparvovec
- ATC code
- M09AX09
- Therapeutic area
- Muscular Atrophy, Spinal
- Marketing authorisation holder
- Novartis Europharm Limited